MDVN : Medivation (NASDAQ: MDVN) is an achievement in the next field of biotechnology. Company high in the waiting phase III study of the Alzheimer’s drug called Dimebon has not met expectations. It failed to achieve the end of primary and secondary education. The problem is that this is 52 to reach the highest level in a week yesterday.
The company did not note that a separate phase 3 safety study of Dimebon showed the tolerability when used alone or in combination with medications approved Alzheimer’s disease. Only one problem … If it does not work no matter how affordable it is. In some cases in the second group did not even the best on the pill and sugar, which may be worse on the company’s approval can be obtained.
Pfizer Inc. (NYSE: PFE) is also lower this morning, as well as he was a partner at Medivation Dimebon to treat Alzheimer’s disease. Reference shares, down about 1% on the news. Keep in mind that Pfizer and at least one other study in the later stages in the fight against Alzheimer’s disease.
The real hit is in Medivation. Sari shares, down about 70% of $ 12.55 on nearly 5 million shares as of 8:28 EST the United States. Before the 52-week trading range was $ 13.36 to $ 40.49.
Medivation the market of 1.35 billion dollars in yesterday’s closing bell. Its most recent balance sheet showed to the north of $ 200 million in cash and investments. Is now going to need every last of that cash.
This is one of those cases where everything has failed in this science. Analysts were positive, and graphics and 52-week trading range was referring to the existence of a green light from being unlikely, there is no significant mismatch between the put and call options trade.
John C. OG
No comments:
Post a Comment